MedTrace Logo

Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study

NCT04084314 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 701

Last updated 2024-10-09

Study results available
· View outcomes & findings →

Summary

This is a 128-week open-label study to assess the long-term safety and tolerabilty of the monoclonal antibody erenumab in migraine patients.

Conditions

  • Migraine
  • Migraine Disorders
  • Migraine Headache

Interventions

BIOLOGICAL

Erenumab

Erenumab was supplied as a pre-filled pen (auto-injector) for subcutaneous injection.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
67 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2023-02-23
Completion
2023-03-13
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04084314 on ClinicalTrials.gov